GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » EPS (Diluted)

Qualis Innovations (Qualis Innovations) EPS (Diluted) : $-0.08 (TTM As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Qualis Innovations EPS (Diluted)?

Qualis Innovations's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.12. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.08.

Qualis Innovations's EPS (Basic) for the three months ended in Dec. 2023 was $0.12. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.08.

Qualis Innovations's EPS without NRI for the three months ended in Dec. 2023 was $0.12. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.08.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Qualis Innovations's highest 3-Year average EPS without NRI Growth Rate was 73.30% per year. The lowest was 30.60% per year. And the median was 52.20% per year.


Qualis Innovations EPS (Diluted) Historical Data

The historical data trend for Qualis Innovations's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualis Innovations EPS (Diluted) Chart

Qualis Innovations Annual Data
Trend Jul06 Jul07 Jul08 Jul09 Jul10 Dec11 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only -1,275.24 20.00 -0.25 -0.11 -0.09

Qualis Innovations Quarterly Data
Jul10 Oct10 Jan11 Apr11 Sep11 Dec11 Mar12 Jun12 Sep12 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.01 -0.19 - 0.12

Competitive Comparison of Qualis Innovations's EPS (Diluted)

For the Medical Devices subindustry, Qualis Innovations's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qualis Innovations's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Qualis Innovations's PE Ratio distribution charts can be found below:

* The bar in red indicates where Qualis Innovations's PE Ratio falls into.



Qualis Innovations EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Qualis Innovations's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.805-0)/8.476
=-0.09

Qualis Innovations's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(0.943-0)/8.476
=0.11

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qualis Innovations  (OTCPK:QLIS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Qualis Innovations EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Qualis Innovations's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualis Innovations (Qualis Innovations) Business Description

Traded in Other Exchanges
N/A
Address
225 Wilmington West Chester Pike, Suite 200, No.145, Chadds Ford, PA, USA, 19317
Qualis Innovations Inc. is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751